MASLD and MASH: Clinical Spectrum and Modern Management, An Issue of Clinics in Liver Disease
- 1 Edición, Volumen 30-2 - 20 de mayo de 2026
- Última edición
- Editor: Zobair M. Younossi
- Idioma: Inglés
In this issue of Clinics in Liver Disease, guest editor Dr. Zobair M. Younossi brings his considerable expertise to the topic of MASH/NASH Fatty Liver. With an estimated 115… Leer más
Descripción
Descripción
In this issue of Clinics in Liver Disease, guest editor Dr. Zobair M. Younossi brings his considerable expertise to the topic of MASH/NASH Fatty Liver. With an estimated 115 million people worldwide affected by MASH, the disease burden casts a wide net: many have other comorbidities, like diabetes, that make diagnosis and treatment critical. MASH-related liver cancer has increased 20% since 1990, and MASH is becoming a leading cause of liver transplants in adults, reflecting its significant impact on liver health. This issue provides state-of-the-art clinical reviews on MASH and NASH and also shines a light on the disease burden across the globe.
Puntos claves
Puntos claves
- Contains 19 relevant, practice-oriented topics including association of MASH with metabolic-related diseases (diabetes, pre-diabetes, and obesity); algorithms for risk stratification in patients with MASH; management of MASLD: lifestyle modification; currently approved and future regimens for MASH; pediatric MASH; and more
- Provides in-depth clinical reviews on MASH/NASH fatty liver, offering actionable insights for clinical practice
- Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field. Authors synthesize and distill the latest research and practice guidelines to create clinically significant, topic-based reviews
De interès para
De interès para
Hepatologists
Índice
Índice
Metabolic Dysfunction-Associated Steatotic Liver Disease: Global Epidemiology, Patient-Reported Outcomes, and Economic Impact
Association of Metabolic Dysfunction-Associated Steatohepatitis with Metabolic- Related Diseases: Diabetes, Prediabetes, and Obesity
Association of Metabolic Dysfunction-Associated Steatotic Liver Disease with Extrahepatic Cancers and Sarcopenia
Metabolic Liver Disease Beyond the Liver: Association of Metabolic Dysfunction- Associated Steatotic Liver Disease with Cardiovascular and Renal Diseases
Noninvasive Testing for Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
Algorithms for Risk Stratification in Patients with Metabolic Dysfunction- Associated Steatohepatitis
Management of Metabolic Dysfunction-Associated Steatotic Liver Disease with Lifestyle Modification
Treatment of Modifiable Risks in Metabolic Dysfunction-Associated Steatotic Liver Disease: Drugs Targeting Obesity and Type 2 Diabetes
Currently Approved and Future Regimens for Metabolic Dysfunction-Associated Steatohepatitis
Special Populations: Hepatocellular Carcinoma Risk and Liver Transplantation
Special Population: Lean MASH
Special Population: A Global Perspective on Metabolic Dysfunction-Associated Alcohol-Related Liver Disease
What’s New in Pediatric Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis
Metabolic Dysfunction-Associated Steatohepatitis in the Middle East: Clinical Challenges and Strategies to Bridge the Gap
Metabolic Dysfunction-Associated Steatotic Liver Disease in Asia: Epidemiology, Clinical Features, and Management
Metabolic Dysfunction-Associated Steatotic Liver Disease in Africa: From Burden to Action
Metabolic Dysfunction-Associated Steatotic Liver Disease in Latin America
Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Oceania, Central America, and the Caribbean
Metabolic Dysfunction-Associated Steatotic Liver Disease and Viral Hepatitis
Association of Metabolic Dysfunction-Associated Steatohepatitis with Metabolic- Related Diseases: Diabetes, Prediabetes, and Obesity
Association of Metabolic Dysfunction-Associated Steatotic Liver Disease with Extrahepatic Cancers and Sarcopenia
Metabolic Liver Disease Beyond the Liver: Association of Metabolic Dysfunction- Associated Steatotic Liver Disease with Cardiovascular and Renal Diseases
Noninvasive Testing for Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
Algorithms for Risk Stratification in Patients with Metabolic Dysfunction- Associated Steatohepatitis
Management of Metabolic Dysfunction-Associated Steatotic Liver Disease with Lifestyle Modification
Treatment of Modifiable Risks in Metabolic Dysfunction-Associated Steatotic Liver Disease: Drugs Targeting Obesity and Type 2 Diabetes
Currently Approved and Future Regimens for Metabolic Dysfunction-Associated Steatohepatitis
Special Populations: Hepatocellular Carcinoma Risk and Liver Transplantation
Special Population: Lean MASH
Special Population: A Global Perspective on Metabolic Dysfunction-Associated Alcohol-Related Liver Disease
What’s New in Pediatric Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis
Metabolic Dysfunction-Associated Steatohepatitis in the Middle East: Clinical Challenges and Strategies to Bridge the Gap
Metabolic Dysfunction-Associated Steatotic Liver Disease in Asia: Epidemiology, Clinical Features, and Management
Metabolic Dysfunction-Associated Steatotic Liver Disease in Africa: From Burden to Action
Metabolic Dysfunction-Associated Steatotic Liver Disease in Latin America
Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Oceania, Central America, and the Caribbean
Metabolic Dysfunction-Associated Steatotic Liver Disease and Viral Hepatitis
Detalles del producto
Detalles del producto
- Edición: 1
- Última edición
- Volumen: 30-2
- Publicado: 23 de mayo de 2026
- Idioma: Inglés
Sobre el editor
Sobre el editor
ZY
Zobair M. Younossi
Afiliaciones y experiencia
Chairman, Department of Medicine, Inova Fairfax Hospital, Vice President for Research, Inova Health System, Professor of Medicine, VCU-Inova Campus, Beatty Center for Integrated Research, USA